Eviora MD review
By Aminoscope editorial desk · Aminoscope
Least identifiable of its cluster
Our verdict
Eviora MD presents well and discloses almost nothing.
Main trade-offs
- No operating company, street address, phone number or principal named anywhere — an email address is the only contact
- "STATES SERVED" heading on the About page has no figure beneath it
Disclosure: Aminoscope is reader-supported. We may earn a commission from partner links, at no extra cost to you. This never changes our assessment. How we make money.
Compounded medicines are not FDA-approved. A licensed clinician must assess whether treatment is appropriate; availability does not establish safety or benefit.
Good fit
Readers set on this shared catalog who do not need the operator, the pharmacy or the state list identified.
Consider other options if
Anyone who wants to know which company they are buying from, or who is comparing this cluster on NAD⁺ price.
Cost and care at a glance
- Category
- GLP-1 telehealth
- Published cost
- "Programs from $149/mo" is the only figure published; no plan table, no address, phone or state list
- Medications
- Compounded semaglutide · Compounded tirzepatide
- Insurance
- Cash-pay, no insurance
- Visit
- Quiz intake / Async intake
- Availability
- Not published
Our review in detail
Full assessment
Eviora MD presents well and discloses almost nothing. The clinical copy is correct — the compounded-medication disclaimer is properly worded, and the trajectory chart is sourced to STEP and SURMOUNT-1 and labeled as trial averages rather than a promise. But a reader trying to work out who they'd be buying from finds an email address and nothing else: no phone, no street address, no named company, no pharmacy, and an About page whose "STATES SERVED" heading has no number under it. Its single GLP-1 figure, "from $149/mo," has no plan table behind it. And its peptide catalog isn't distinctively its own — on NAD⁺ it's $40 more expensive than the same SKU at RX Bella.
What it is
A self-described concierge telehealth platform selling compounded GLP-1 weight-loss care, a lower-dose microdose program, NAD⁺ and a six-focus-area peptide menu. It states it facilitates access to independent US board-certified providers and state-licensed compounding pharmacies and does not practice medicine, prescribe or dispense. Beyond the brand name and an info@ email address, it identifies no company, principal, address or phone number anywhere on the site.
How care works
Asynchronous, via an online eligibility check and consultation, with structured check-ins and secure messaging described. Medication is "prepared by partner compounding pharmacies in the United States," never named. No footprint is published at all: the About page includes a "STATES SERVED" heading with nothing beneath it, and no page enumerates a state list. Its peptide and NAD⁺ catalog is shared verbatim with RX Bella and New Wave Health — the same SKUs at the same prices with the same per-product descriptions and the same six numbered focus areas — with NAD⁺ injection the only price that varies across the three.
Costs, billing and cancellation
One figure, no table. "GLP-1 weight loss programs from $149/mo" runs in the announcement bar and hero, and "Plans from $149/mo · confirmed after provider review" appears under the BMI tool; the semaglutide, tirzepatide and microdose treatment pages carry no price at all. Nothing states what the figure includes, whether it survives dose escalation, or what commitment it requires. The peptide side is fully priced from the shared catalog: BPC-157 acetate $199/mo, BPC-157 $250, sermorelin $249, epithalon $249, GHK-Cu $249, PT-141 $249, MOTS-C $279, tesamorelin $299, thymosin alpha-1 $299, semax/selank $299, GHK-Cu/epithalon $319, CJC-1295/ipamorelin $329, blends to $379, NAD⁺ injection $199. That NAD⁺ line is $159 on RX Bella for the identical product described in identical words.
Medication and evidence
Compounded semaglutide and tirzepatide, a GLP-1 microdose program, injectable NAD⁺, and the shared nineteen-SKU peptide menu. Like RX Bella and unlike New Wave Health, it files BPC-157/GHK-Cu/KPV/TB500 and BPC-157/TB-500/GHK-Cu under "Anti-Aging & Growth Hormone" and describes them as "a copper peptide," which describes one ingredient of a blend that is neither primarily copper nor a growth-hormone product. On the evidence: the GLP-1 outcome data belongs to the branded products, not compounded copies; injectable NAD⁺ and the growth-hormone secretagogues are compounded, not FDA-approved, and have no controlled human outcome trials for the uses they are marketed on.
Pros and watch-outs
What we like
- Compounded-medication disclaimer correctly worded and prominent
- Cites STEP (NEJM 2021) and SURMOUNT-1 (NEJM 2022) properly and labels its chart as trial averages
- Peptide and NAD⁺ menu fully priced, unlike its GLP-1 line
- States plainly that eligibility is determined only after provider evaluation
Watch-outs
- No operating company, street address, phone number or principal named anywhere — an email address is the only contact
- "STATES SERVED" heading on the About page has no figure beneath it
- One GLP-1 price published and no plan table; treatment pages carry no price at all
- NAD⁺ is $199 for the identical SKU RX Bella sells at $159
- Peptide catalog, prices and descriptions identical to two other brands; blends filed under the wrong category
- Dispensing pharmacy never named; no LegitScript certification referenced
Best for
Readers set on this shared catalog who do not need the operator, the pharmacy or the state list identified.
Who should look elsewhere
Anyone who wants to know which company they are buying from, or who is comparing this cluster on NAD⁺ price.
Research relevant to Eviora MD
Explore the evidence and its limits. Findings apply to the formulation, route and population studied; they do not establish the quality or effectiveness of a provider’s products.
- What the semaglutide weight-loss trials actually showed
STEP 1, STEP 4 and SELECT, plus oral and higher-dose semaglutide trials: weight loss, withdrawal, cardiovascular benefit and the limits of comparison.
- Tirzepatide vs semaglutide for weight loss: what the trials actually support
SURMOUNT-5 found 20.2% versus 13.7% average weight loss. What that direct comparison supports, which doses it tested, and why newer formulations need separate evidence.
- NAD+ injections: benefits, side effects, cost and what the evidence says
Subcutaneous NAD+ is sold as a cheaper, at-home alternative to the IV drip, through “near me” clinics or telehealth shipped to your door. It is compounded, not FDA-approved for wellness uses. Small IV studies and oral-precursor trials do not establish long-term benefits from home NAD+ injections.
- Sermorelin benefits: does it work? What the trials show
A real GHRH drug, read against the anti-aging pitch: an approved growth-hormone-releasing analog with a pediatric track record, and a longevity case built more on biomarkers than outcomes.
- BPC 157: what the evidence actually shows (and what it doesn't)
The 'healing peptide' has a deep rodent literature and almost no human data. A straight read of where the science stands.
- MOTS-c peptide: benefits, side effects and what the evidence shows
Real mitochondrial biology, absent human evidence: a genuine mitochondrial-derived peptide with interesting rodent data on metabolism and exercise, but no human outcome trials. Promising biology, not a proven therapeutic.
- PT-141 (bremelanotide): the evidence on a peptide that is actually FDA-approved
Bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women, with phase-3 trial evidence. A straight read of what's proven — and where off-label use goes beyond it.
How Eviora MD compares
A few alternatives worth a look, depending on what you’re optimizing for.
Enhance MDLab-guided treatment under ongoing physician oversight
See Enhance MD →- HealthRX
Low-cost compounded GLP-1 with overnight shipping and physician review
See HealthRX → 
RX BellaReaders who want GLP-1, NAD⁺ and peptides from one brand and will price it from the catalog, not the banner
See RX Bella →
More GLP-1 telehealth reviews: AlyveRxAM RxChronos Body Health & WellnessCieloCitizen MedsClaya
Editorial research
How we assessed this. This review reflects Aminoscope’s own read of Eviora MD’s publicly-stated model — pricing transparency, clinical oversight, medication clarity, and access — against our editorial methodology. We publish no fabricated ratings or first-hand outcomes. A partnership never changes the assessment — see how we make money.
Frequently asked
- Who operates Eviora MD?
- The site does not say. There is a general info email address and no phone number, no street address, no named operating company or principal, and no LegitScript reference. Its own disclaimer identifies "Eviora MD" as a platform facilitating access to independent providers and compounding pharmacies, none of which is named either. Its two sister brands publish at least a phone number, and New Wave Health publishes a full street address.
- What does Eviora MD cost?
- It publishes "from $149/mo" and nothing else. The semaglutide, tirzepatide and microdose treatment pages carry no price, there is no plan table, and nothing states what the figure covers, whether it holds as your dose rises, or what commitment earns it. Its peptide catalog is fully priced, which makes the absence on the GLP-1 side look like a choice rather than an oversight. If a published price matters, Idgie Health, No BS RX, Prime Doctor RX, Edessa and Rx.com all table theirs.
- Is Eviora MD's NAD⁺ competitively priced?
- Not against its own sister brand. Eviora sells NAD⁺ injection at $199/month; RX Bella sells the identical SKU, described in identical words inside an identical catalog, at $159. That is a $40 monthly difference — about $480 a year — for what the sites themselves present as the same product. New Wave Health also charges $199. If you are buying NAD⁺ from this cluster, RX Bella is the cheaper door.
- Is the peptide catalog Eviora MD's own?
- No. RX Bella and New Wave Health publish the same menu — the same SKUs at the same prices, the same per-product sentences, the same six numbered focus areas and the same "Precision peptides, guided by your goal" hero. All three run the same disclaimer boilerplate with the brand name swapped. They are separate businesses with separate reviews, but a reader comparing them on peptides is comparing three front doors to one catalog.
- Is Eviora MD legit?
- Eviora MD is a GLP-1 telehealth service you reach through an online questionnaire and an online intake a clinician reviews. The medications it names are Compounded semaglutide and Compounded tirzepatide. What it publishes up front: "Programs from $149/mo" is the only figure published; no plan table, no address, phone or state list. It is cash-pay and states it does not bill insurance. Before you pay, ask in writing about which states it serves.
- Is Eviora MD expensive compared with other GLP-1 telehealth providers?
- Eviora MD publishes a starting figure of $149/mo. Across the 110 GLP-1 telehealth providers we review that publish a single monthly figure, those run $49 to $399 with a median of $189, which puts Eviora MD below the median, toward the cheaper end. The other 285 GLP-1 telehealth providers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.